Taurocholzuur-d5

Taurocholic acid-d5 (Taurocholic Acid-d5) is deuterium labeled Taurocholic acid. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect[1].

2044276-13-1

N-Choloyltaurine-d5

12352100

Endogenous Metabolite; Isotope-Labeled Compounds

Metabolic Enzyme/Protease; Others

COVID-19-immunoregulation

Inflammation/Immunology

O=C(CC[C@H]([C@@]1([C@]2([C@H](C[C@]3([C@@]([H])([C@@H](C[C@@]4(C([2H])([C@@]([2H])(C([2H])(C[C@@]43C)[2H])O)[2H])[H])O)[C@@]2(CC1)[H])[H])O)C)[H])C)NCCS(=O)(O)=O

C26H40D5NO7S

520.73

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Xun Z, et al. Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8+ T and NK cell function. Cell Mol Immunol. 2021 Feb;18 (2) :461-471. |[3]Glaser S, et al. Taurocholic acid prevents biliary damage induced by hepatic artery ligation in cholestatic rats. Dig Liver Dis. 2010 Oct;42 (10) :709-17.|[4]Okabe S, et al. Effects of L-glutamine of acetylsalicylic acid or taurocholic acid-induced gastric lesions and secretory changes in pylorus-ligated rats under normal or stress conditions. Jpn J Pharmacol. 1976 Aug;26 (4) :455-60. |[5]Mooranian A, et al. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study. Drug Deliv Transl Res. 2015 Oct;5 (5) :511-22.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-B1788S2/

Isotope-Labeled Compounds

No Development Reported